Open Label, Dose Escalation Study of Paricalcitol (Zempla) [19-NOR-1 ALPHA, 25-(OH) D] in Combination With Gemcitabine [2', 2' -Difluorodeoxycytidine] in Patients With Advanced Malignancies.
Phase of Trial: Phase I
Latest Information Update: 09 Oct 2018
At a glance
- Drugs Gemcitabine (Primary) ; Paricalcitol (Primary)
- Indications Cancer
- Focus Adverse reactions
- 09 Oct 2018 Results published in the Cancer
- 08 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 11 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.